J9054
J9054 – Inj bortezomib boruzu 0.1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked per 0.1 MG $24.747/unit ASP+6%
📋 J9054 summary
J9054 is a HCPCS Level II J-code used to bill bortezomib boruzu 0.1 mg, billed per 0.1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9054: Boruzu
Code J9054
Billing unit 0.1 MG Payment limit $24.747/unit NDC-Crosswalk 1
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9054
DescriptorInj bortezomib boruzu 0.1 mg
Billing unit0.1 MG
Payment limit / unit$24.747
Est. ASP / unit$23.346 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20
💊 About Bortezomib DRUG GUIDE
Bortezomib is used to treat two types of cancer in adults: multiple myeloma (a cancer of plasma cells in the bone marrow) and mantle cell lymphoma (a type of non-Hodgkin lymphoma).
These indications are shared across the available products — Velcade, Boruzu, and generic bortezomib formulations.Velcade, Boruzu, and bortezomib injections are all approved for both conditions.
Your care team will determine which product and treatment plan is right for your situation.
Clinical overview from our editorial drug guide for Bortezomib. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$24.747
Est. ASP / unit
$23.346 est.
Est. after 2% sequester
$24.252
HCPCS dosage
0.1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9054 = 0.1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9054 WITH EST. MEDICARE PAY
1 NDC map to J9054. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($24.747/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 70121-2484-01 | BORUZU Bortezomib 3.5 mg/1.4mL INJECTION | Amneal | 1 VIAL, SINGLE-DOSE in 1 CARTON (70121-248... | 3.5 mg/1.4mL | 35 | $866.15 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$2.41M
Claims
2,691
Beneficiaries
656
Spend / beneficiary
$3,671.40
Spend / claim
$895.00
Trend by period
Where J9054 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #307 of 824
#302
ZOLADEX J9202
$2.65M
#303
BELRAPZO* J9036
$2.6M
#304
JIVI J7208
$2.56M
#305
SUSVIMO J2779
$2.53M
#306
GELSYN-3 J7328
$2.43M
#307
BORUZU J9054
$2.41M
#308
FYARRO J9331
$2.4M
#309
PANHEMATIN J1640
$2.4M
#310
EPYSQLI Q5151
$2.38M
#311
BELEODAQ J9032
$2.35M
#312
LOQTORZI J3263
$2.35M
Total claims — #279 of 824
#274
KERECIS OMEGA3, PER... Q4158
2,810
#275
GRAFIX STRAVIX PRIME... Q4133
2,788
#276
VANCOMYCIN HCL-0.9%... J3373
2,740
#277
CALCIUM GLUCONATE-NA... J0612
2,730
#278
ELAHERE J9063
2,700
#279
BORUZU J9054
2,691
#280
DYSPORT J0586
2,683
#281
IDOSE TR J7355
2,681
#282
DARZALEX J9145
2,647
#283
KRYSTEXXA J2507
2,633
#284
EOVIST A9581
2,602
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $2.41M | 656 | 2,691 | $3,671.40 | $895.00 |
| 2025 (Q1-Q4) | $1.39M | 278 | 1,554 | $5,010.57 | $896.36 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$1.3M
Medicare paid
$1.02M
Submitted services
52,637
Denial rate
4.9%
Allowed / service
$26.03
Submitted charges
$3.46M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9054 is utilized
⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.
📊 What bills under J9054
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Not available in current dataset
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9054 billing FAQ
What is HCPCS code J9054?
J9054 is a HCPCS Level II J-code used to bill Inj bortezomib boruzu 0.1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9054?
One unit of J9054 represents 0.1 MG. Report the number of units equal to the dose administered divided by 0.1 MG.
How many units of J9054 should I bill?
Divide the dose administered by the code's unit size (0.1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9054?
The Medicare Part B payment limit is $24.747 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $24.252 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9054?
1 NDC currently map to J9054 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9054 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.